Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells
Abstract Background Uveitis is a potentially blinding inflammatory disease of the inner eye with a high unmet need for new therapeutic interventions. Here, we wanted to investigate the suppressive effect of the intraocular application of the small molecule dihydroorotate dehydrogenase (DHODH)-inhibi...
Main Authors: | Maria Diedrichs-Möhring, Sandy Niesik, Claudia S. Priglinger, Stephan R. Thurau, Franz Obermayr, Stefan Sperl, Gerhild Wildner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Journal of Neuroinflammation |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12974-018-1088-6 |
Similar Items
-
A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis — A phase I clinical trial
by: Stephan Thurau, et al.
Published: (2022-10-01) -
Molecular Mimicry and Uveitis
by: Gerhild Wildner, et al.
Published: (2020-10-01) -
DHODH and cancer: promising prospects to be explored
by: Yue Zhou, et al.
Published: (2021-05-01) -
A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression
by: Yongrui Hai, et al.
Published: (2024-04-01) -
Targeting DHODH reveals therapeutic opportunities in ATRA-resistant acute promyelocytic leukemia
by: Tingyuan Yang, et al.
Published: (2023-10-01)